The NDA for SPN-830 is supported by data from an extensive development program that includes the phase 3 TOLEDO study and a supportive open-label study.
Researchers conducted an 8-week, open-label, single-arm study and a subsequent 2-stage, sequential, parallel comparison study to assess the use of pimavanserin among patients with Parkinson disease and major depressive disorder.
In early Parkinson Disease, fatigue, excessive daytime sleepiness, and emotional apathy are predictive of increasing fatigue severity.
Participants in the multidisciplinary intervention group had significant improvements in verbal learning and memory, attention, cognitive flexibility, and processing speed.
Increased adherence to alternate Mediterranean and Alternative Healthy Eating Index dietary patterns is inversely associated with prodromal features of Parkinson disease.
A Phase 1 trial suggested that PD01A was safe and well tolerated over an extended period in patients with Parkinson disease.
Compared with optimal medical therapy alone, deep brain stimulation can decrease the risk for disease progression in patients with early-stage Parkinson disease.
The earliest brain changes due to Huntington disease can be detected in cerebrospinal fluid 24 years before clinical symptoms show.
Researchers sought to determine the relationship between neuroimaging markers and other clinical characteristics with mild parkinsonian signs in older adults.
Results from a sleep study indicate a reduced circadian rhythmicity is associated with an increased risk for incident Parkinson disease.